blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2428229

EP2428229 - ONCOLYTIC ADENOVIRUSES FOR TREATING CANCER [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  04.02.2019
Database last updated on 20.12.2024
Most recent event   Tooltip01.10.2024New entry: Despatch of interlocutory decision 
Applicant(s)For all designated states
Fundació Privada Institut D'investigació Biomèdica
Hospital Duran i Reynals, 3ª planta
Gran Via de l ́Hospitalet, 199
08908 Hospitalet de Llobregat
Barcelona / ES
For all designated states
Institut Català D'Oncologia
Gran Via s/n 199-203
08907 L'Hospitalet de Llobregat / ES
[2016/31]
Former [2012/11]For all designated states
Fundació Privada Institut D'investigació Biomèdica
Gran Via s/n - km. 2 7
08907 L'Hospitalet de Llobregat / ES
For all designated states
Institut Català D'Oncologia
Gran Via s/n 199-203
08907 L'Hospitalet de Llobregat / ES
Inventor(s)01 / GUEDAN CARRIÓ, Sònia
Sant Ramon 6 baixos
E-08242 Manresa / ES
02 / CASCALLO PIQUERAS, Manel Maria
Pg. Circumval.lació 54 2n
E-08790 Gelida / ES
03 / ALEMANY BONASTRE, Ramon
Passatge del Cim 19
E-08860 Castelldefels / ES
 [2012/11]
Representative(s)ABG Intellectual Property Law, S.L.
Avenida de Burgos, 16D
Edificio Euromor
28036 Madrid / ES
[N/P]
Former [2016/31]ABG Patentes, S.L.
Avenida de Burgos, 16D
Edificio Euromor
28036 Madrid / ES
Former [2012/11]ABG Patentes, S.L.
Avenida de Burgos 16D Edificio Euromor
28036 Madrid / ES
Application number, filing date10772050.005.05.2010
[2016/31]
WO2010ES00196
Priority number, dateES2009000120106.05.2009         Original published format: ES 200901201
[2012/11]
Filing languageES
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010128182
Date:11.11.2010
Language:ES
[2010/45]
Type: A1 Application with search report 
No.:EP2428229
Date:14.03.2012
Language:EN
[2012/11]
Type: B1 Patent specification 
No.:EP2428229
Date:03.08.2016
Language:EN
[2016/31]
Search report(s)International search report - published on:ES11.11.2010
Supplementary international search report - requested on:EP06.12.2010
ClassificationIPC:C12N15/861, A61K48/00, C12N9/26
[2016/01]
CPC:
C07K14/005 (EP,CN,US); A61K35/761 (EP,CN,US); A61K48/00 (ES);
A61P35/00 (EP); C12N15/86 (EP,CN,US); C12N15/861 (ES);
C12N7/00 (EP,CN,US); C12N9/2474 (EP,CN,ES,US); A61K38/00 (EP,CN,US);
C12N2710/10321 (EP,CN,US); C12N2710/10322 (EP,CN,US); C12N2710/10332 (EP,CN,US);
C12N2710/10343 (EP,CN,US); C12N2710/10371 (EP,CN,US) (-)
Former IPC [2012/11]A61K48/00, C12N15/861
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/11]
Extension statesBA30.11.2011
ME30.11.2011
RS30.11.2011
TitleGerman:ONKOLYTISCHE ADENOVIREN ZUR BEHANDLUNG VON KREBS[2012/11]
English:ONCOLYTIC ADENOVIRUSES FOR TREATING CANCER[2012/11]
French:ADÉNOVIRUS ONCOLYTIQUES POUR LE TRAITEMENT DU CANCER[2012/11]
Entry into regional phase30.11.2011Translation filed 
30.11.2011National basic fee paid 
30.11.2011Designation fee(s) paid 
30.11.2011Examination fee paid 
Examination procedure30.11.2011Amendment by applicant (claims and/or description)
30.11.2011Examination requested  [2012/11]
22.10.2014Despatch of a communication from the examining division (Time limit: M04)
27.02.2015Reply to a communication from the examining division
26.01.2016Communication of intention to grant the patent
03.06.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
03.06.2016Fee for grant paid
03.06.2016Fee for publishing/printing paid
22.06.2016Information about intention to grant a patent
22.06.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.10.2014
Opposition(s)Opponent(s)01  03.05.2017  08.05.2017  ADMISSIBLE
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastrasse 30
81925 München / DE
 [2021/15]
Former [2017/23]
Opponent(s)01  03.05.2017  08.05.2017  ADMISSIBLE
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastrasse 30
81925 München / DE
Former [2017/23]
Opponent(s)01  03.05.2017    ADMISSIBLE
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastrasse 30
81925 München / DE
08.06.2017Invitation to proprietor to file observations on the notice of opposition
18.10.2017Reply of patent proprietor to notice(s) of opposition
15.11.2018Date of oral proceedings
05.02.2019Despatch of minutes of oral proceedings
05.02.2019Despatch of communication that the patent will be revoked
05.02.2024Despatch of a communication from the opposition division (Time limit: M02)
05.04.2024Reply to a communication from the opposition division
30.09.2024Despatch of interlocutory decision in opposition
Appeal following opposition05.04.2019Appeal received No.  T1203/19
17.06.2019Statement of grounds filed
26.04.2022Result of appeal procedure: maintenance in amended form
18.07.2023Despatch of the decision of the Board of Appeal
26.04.2022Date of oral proceedings
Petition(s) for review:20.09.2023Petition for review received
 Number:  R0015/23
 for appeal No.  T1203/19-3308
 Petitioner:  OP01
03.07.2024Decision:  Withdrawal of the petition for review.
Fees paidRenewal fee
08.03.2012Renewal fee patent year 03
10.05.2013Renewal fee patent year 04
07.03.2014Renewal fee patent year 05
12.03.2015Renewal fee patent year 06
07.04.2016Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.05.2010
AL03.08.2016
CY03.08.2016
CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
MC03.08.2016
MK03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
TR03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU05.05.2017
MT05.05.2017
[2020/15]
Former [2019/51]HU05.05.2010
AL03.08.2016
CY03.08.2016
CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
MC03.08.2016
MK03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU05.05.2017
MT05.05.2017
Former [2019/46]HU05.05.2010
AL03.08.2016
CY03.08.2016
CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
MC03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU05.05.2017
MT05.05.2017
Former [2019/31]HU05.05.2010
AL03.08.2016
CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
MC03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU05.05.2017
MT05.05.2017
Former [2018/46]AL03.08.2016
CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
MC03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU05.05.2017
MT05.05.2017
Former [2018/43]CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
MC03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU05.05.2017
MT05.05.2017
Former [2018/17]CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
MC03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU05.05.2017
Former [2018/06]CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
MC03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU31.05.2017
Former [2017/37]CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
RO03.08.2016
SI03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
LU31.05.2017
Former [2017/32]CZ03.08.2016
DK03.08.2016
EE03.08.2016
HR03.08.2016
LT03.08.2016
LV03.08.2016
RO03.08.2016
SK03.08.2016
SM03.08.2016
BG03.11.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
Former [2017/13]HR03.08.2016
LT03.08.2016
LV03.08.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
Former [2017/11]HR03.08.2016
LT03.08.2016
NO03.11.2016
GR04.11.2016
IS03.12.2016
PT05.12.2016
Former [2017/09]LT03.08.2016
NO03.11.2016
Former [2017/07]LT03.08.2016
Cited inInternational search[A]WO2005018332  (GEN HOSPITAL CORP [US], et al);
OppositionWO2004078140
 WO2005018332
 WO2006091871
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.